Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Table 3 mRNA expression levels in normal and breast cancer subtypes

Gene	Subtype or normal ^a	Log ₂ (normalized counts) ^b	Comparison with basal ^c
CDC2L1	Normal	9.39 ± 0.38	0.90
	Basal	9.51 ± 0.5	N/A
	Her2	9.45 ± 0.61	1
	Luminal A	9.46 ± 0.4	1
	Luminal B	9.33 ± 0.57	0.049
CDC2L2	Normal	8.35 ± 0.76	−^d
	Basal	8.37 ± 0.79	N/A
	Her2	8.49 ± 0.84	–
	Luminal A	8.44 ± 0.69	–
	Luminal B	8.24 ± 0.95	–
CCNL1	Normal	10.82 ± 0.58	1.37 × 10 ⁻¹⁴
	Basal	10.15 ± 0.56	N/A
	Her2	9.7 ± 0.49	9.68 × 10 ⁻⁷
	Luminal A	9.87 ± 0.55	2.17 × 10 ⁻⁵
	Luminal B	9.85 ± 0.49	2.10 × 10 ⁻⁵
CCNL2	Normal	10.79 ± 0.48	1.90 × 10 ⁻¹¹
	Basal	10.2 ± 0.71	N/A
	Her2	10 ± 0.73	1
	Luminal A	10.38 ± 0.7	0.21
	Luminal B	10.28 ± 0.7	1
CSNK2A1	Normal	10.22 ± 0.2	5.50 × 10 ⁻¹⁵
	Basal	10.74 ± 0.64	N/A
	Her2	10.75 ± 0.51	1
	Luminal A	10.53 ± 0.39	9.20 × 10 ⁻³
	Luminal B	10.68 ± 0.61	1
CSNK2A2	Normal	9.36 ± 0.3	1
	Basal	9.3 ± 0.39	N/A
	Her2	8.92 ± 0.56	3.89 × 10 ⁻⁵
	Luminal A	8.56 ± 0.45	2.06 × 10 ⁻⁴⁹
	Luminal B	8.64 ± 0.47	2.99 × 10 ⁻³³
CSNK2B	Normal	10.96 ± 0.28	3.03 × 10 ⁻³⁸
	Basal	11.78 ± 0.5	N/A
	Her2	11.52 ± 0.39	1.91 × 10 ⁻³
	Luminal A	11.25 ± 0.42	4.04 × 10 ⁻²²
	Luminal B	11.43 ± 0.54	8.24 × 10 ⁻⁸

Her2, human epidermal growth factor receptor 2; N/A, not applicable. ^aNormal, n = 95; basal, n = 141; Her2, n = 67; luminal A, n = 421; luminal B, n = 192. ^bRNAseq data from The Cancer Genome Atlas expressed as mean ± standard deviation. ^cComparison with basal subtype, P value with Bonferroni correction; significant P values in bold type. ^dAnalysis of variance comparing CDC2L2 expression across subtypes revealed no significant differences, so no pairwise t tests were performed.

ISSN: 1465-542X